ciprofibrate has been researched along with Hyperlipoproteinemia Type III in 1 studies
Hyperlipoproteinemia Type III: An autosomal recessively inherited disorder characterized by the accumulation of intermediate-density lipoprotein (IDL or broad-beta-lipoprotein). IDL has a CHOLESTEROL to TRIGLYCERIDES ratio greater than that of VERY-LOW-DENSITY LIPOPROTEINS. This disorder is due to mutation of APOLIPOPROTEINS E, a receptor-binding component of VLDL and CHYLOMICRONS, resulting in their reduced clearance and high plasma levels of both cholesterol and triglycerides.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Richard, P | 1 |
| de Zulueta, MP | 1 |
| Beucler, I | 1 |
| De Gennes, JL | 1 |
| Cassaigne, A | 1 |
| Iron, A | 1 |
1 other study available for ciprofibrate and Hyperlipoproteinemia Type III
| Article | Year |
|---|---|
Identification of a new apolipoprotein E variant (E2 Arg142-->Leu) in type III hyperlipidemia.
Topics: Aged; Amino Acid Sequence; Apolipoproteins E; Clofibric Acid; Fibric Acids; Genotype; Humans; Hyperl | 1995 |